Akebia amends Auryxia supply agreement with Siegfried; extends term to Dec 2024 with option to 2026

Akebia Therapeutics, Inc.

Amendment No. 5 to Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA.
Akebia commits to purchase minimum quantity of Auryxia drug substance at predetermined price.
Term extended to Dec 31, 2024; Company has option to extend to Dec 31, 2026 with 12 months notice.
No other financial terms disclosed in the filing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Akebia Therapeutics, Inc. amended Amendment No. 5 to Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA (effective 2022-02-28).

Action: amendment
Agreement: supply
Counterparty: Siegfried Evionnaz SA
Effective: 2022-02-28

Exact text from the filing

On February 28, 2022, Keryx Biopharmaceuticals, Inc., a wholly-owned subsidiary of Akebia Therapeutics, Inc. (the “Company”), and Siegfried Evionnaz SA (“Siegfried”) entered into Amendment No. 5 to Master Manufacturing Services and Supply Agreement (the “Amendment”), which further amends the Master Manufacturing Services and Supply Agreement dated December 20, 2017 (as amended, the “Supply Agreement”).

View on SEC.gov

Browse all material agreements →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-058118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.